Technical Data
c-erbB2 ( HER2/neu, ErbB2, ErbB-2, Tyrosine Kinase-type Cell Surface Receptor Her2, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, HER2, HER-2, NEU, NGL, Neuroblastoma- or Glioblastoma-Derived Oncogene Homolog, TKR1)
HER2 / ErbB2 is one of the four members of the ErbB receptor family of transmembrane receptor-like tyrosine kinases (1). The kinase activity of ErbB2 can be activated without ligand if it is overexpressed, and by association with other ErbB proteins (2). Overexpression of ErbB2 is detected in almost 40% of human breast cancers (3). Binding of c-Cbl ubiquitin ligase to Tyr1112 of ErbB2 leads to poly-ubiquitination of ErbB2 and enhances its degradation (4). ErbB2 is one of the major targets for the treatment of breast cancer and other carcinomas.

Suitable for use in Flow Cytometry, Western Blot, Immunoprecipitation and Immunohistochemistry. Other applications not tested.

Recommended Dilutions:
Flow Cytometry: 1:30
Western Blot: 1:50,000-1:100,000
Immunoprecipitation: 1:50
Immunohistochemistry: 1:100-1:250
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. 

Manufactured incorporating RabMAb® technology under Epitomics US patents, No 5,675,063 and 7,429,487, owned by Abcam.
100ul-20°CBlue IceHumanRabbit
Not Determined
Synthetic peptide corresponding to residues near the C-terminus of human c-erbB2.
Supplied as a liquid in 50mM Tris-glycine, pH 7.4, 0.15M sodium chloride, 0.05% BSA, 0.01% sodium azide, 40% glycerol.
Recognizes human c-erbB2 phosphorylated at Tyr1248 as well as unphosphorlyated c-erbB2 at ~185kD.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Muthuswamy, S. K., et al. Mol. Cell. Biol. 19: 6845-6857 1999). 2. Qian, X., et al. Proc. Natl. Acad. Sci. USA 91: 1500–1504 1994). 3. Dittadi, R, et al. J. Natl. Cancer Inst. 92: 1443-1444 (2000). 4. Klapper, L. N., et al. Cancer Res. 60: 3384-3388 (2000).